Credits: Alfa Photo/Shutterstock.com.

GlobalData conducted a survey to assess the prospective growth in the post-pandemic DCT use.

Around 67% of the surveyed respondents, who had never used DCTs before, said that they intend to transit from traditional trials now due to the pandemic.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

COVID-19 pandemic fuelled transition towards DCT

Is COVID-19 the Reason You Will Begin Using Decentralised Trials for the First time?

In the Rest of World (RoW) region, around 50% of the respondents highlighted COVID-19 as the biggest reason for the switch.

The figure stood at 47%, 46% and 36% in North America, Asia Pacific and Europe regions, respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The analysis is based on responses received from the GlobalData, Coronavirus Survey – Pharmaceutical Imports/Exports and Supply Chain survey- fielded between 04 June 2020 to 22 June 2020.